Theradexå¨

What Theradexå¨ does

Theradex Oncology (legally Theradex Systems, Inc.) is a privately held, oncology-only contract research organization (CRO) founded in 1982 and headquartered in Princeton, New Jersey. The company delivers full-service clinical trial support to global pharmaceutical and biotechnology companies, emerging biotech sponsors, and the U.S. National Cancer Institute (NCI), covering pre-IND regulatory strategy through late-phase oncology trials, including data management, clinical monitoring, medical writing, biostatistics, pharmacovigilance, and project management. Theradex has held consecutive Clinical Trials Monitoring Services (CTMS) contracts with the NCI since 1982, with the current agreement extending to May 2032, and monitors all protocols under the NCI's Experimental Therapeutics Clinical Trials Network (ETCTN) launched in 2014.

The company's technology stack is built around a proprietary integrated platform: a centralized Clinical Trial Management System (CTMS), the Monitor Express site-monitoring workflow tool, a configurable IWRS Patient Registration System, Cohort Management with automated site notifications, a web-based Drug Inventory Management System, EDC capabilities (with experience on Medidata Rave and Merative Zelta), an Oracle Argus-based Pharmacovigilance Management System, and a SharePoint-backed secure Client Portal. These systems are supported by a 24/7 Help Desk and are differentiated in oncology-specific configurations such as rapid cohort open/close for dose-escalation studies. Theradex maintains compliance with HIPAA, GDPR, UK GDPR, PIPEDA, the EU-U.S. Data Privacy Framework, 21 CFR Part 11, ICH E6 GCP, and related global GxP frameworks.

Theradex operates on a project-based, contract-priced B2B model with multi-year engagements and engages clients primarily through direct enterprise sales, senior leadership involvement, and conference-driven outreach at AACR, ASCO, ESMO, ASH, and BIO. The company has approximately 170 oncology experts (including 17 full-time oncologists and PhDs), operates from offices in Princeton (US HQ), Crawley (UK, European HQ), and Gothenburg (Sweden), and runs trials across 16 countries spanning North America, Europe, Asia Pacific, and the Middle East. The executive team is led by President & CEO Meg Valnoski (20+ years in role) and includes senior personnel with prior leadership tenure at NCI's Cancer Therapy Evaluation Program, Bristol-Myers Squibb, KPMG, and publicly listed European life sciences companies.

Name

Theradexå¨

Legal name

Theradex Systems, Inc.

Website

https://theradex.com

Company type

Private

Founded year

1982

Operating status

Operating

Headcount range

101–250 employees

Short description

Theradex Oncology is a private, oncology-only CRO founded in 1982 that delivers full-service clinical trial management, data, monitoring, and regulatory services to global pharma/biotech sponsors, emerging biotechs, and the U.S. National Cancer Institute.

Ownership category

akta.pro rank

Product category

Oncology Clinical Research Organization (CRO) Services

NAICS

Scientific Research and Development Services (5417)

SIC

Services-Health Services (8000)

akta.pro primary industry

Clinical Trial Site Operations & Study Coordination (HLAGACAE)

akta.pro secondary industry

Clinical Trial Monitoring Support (On-site/Remote) (HLAGACAG)

Keywords

• Oncology clinical trials
• Clinical research organization
• Pharmacovigilance services
• Clinical trial management system
• Regulatory consulting oncology

Headquarters

HQ city

Princeton

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Research Organization Services: Full-service oncology-focused CRO providing comprehensive clinical trial services including clinical monitoring, data management, regulatory consulting, pharmacovigilance, medical writing, biostatistics, and project management. Revenue generated through professional service contracts with pharma/biotech companies and government contracts (NCI).

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Theradex Oncology is a full-service, oncology-only Contract Research Organization that provides end-to-end clinical trial services for pharmaceutical, biotechnology, and government sponsors. Its offering bundles MD-led clinical monitoring, clinical data management, pharmacovigilance, regulatory consulting, medical writing, biostatistics, project management, and quality assurance with a proprietary, integrated clinical trial technology stack (CTMS, IWRS, EDC, pharmacovigilance, drug inventory, and document management). The company has operated the NCI Clinical Trials Monitoring Service contract since 1982 and supports oncology trials globally across 16 countries.

Product overview

Theradex Oncology is a full-service, oncology-focused clinical trial provider offering a platform-plus-services model. The technology portfolio centers on proprietary clinical trial management systems including the Clinical Trial Management System (CTMS), Monitor Express, Theradex IWRS Patient Registration System, Cohort Management, Drug Inventory Management, EDC Systems, Pharmacovigilance Management System, Document Management, and NCI Service Portal. These technology products are complemented by a comprehensive suite of CRO services spanning Clinical Data Management, Clinical Monitoring, Medical Writing, PK/PD Analyses, DSMB Support, Pharmacovigilance, Project Management, Quality Assurance, Regulatory Consulting, and Biostatistical & Programming Services. All systems are fully integrated and supported by a 24/7 Help Desk.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Data Management Comprehensive clinical data management services for oncology sponsors covering document development, EDC study builds, and end-to-end data project management to ensure accurate, compliant, and efficient data handling across trials.
• Clinical Monitoring Dedicated clinical monitoring for oncology trials covering onsite and remote monitoring, site qualification, initiation, and close-out services to ensure site compliance, patient safety, and data integrity.
• Medical Writing Compliant medical writing and documentation for oncology trials including protocols, clinical study reports (CSRs), investigator brochures, and regulatory submission documents.
• Pharmacokinetic (PK) and Pharmacodynamic (PD) Analyses PK/PD analyses and exploratory study support for oncology drug development including in-house scientific and biostatistical review, vendor management, and scientific review of PK reports.
• DSMBs, SRCs, and IDSMBs Support Comprehensive support for Data Safety Monitoring Boards (DSMBs), Safety Review Committees (SRCs), and Independent DSMBs (IDSMBs) including committee recruitment, charter development, and data support for safety and efficacy assessments in oncology trials.
• Pharmacovigilance Services Comprehensive pharmacovigilance services for oncology sponsors covering database configuration, adverse event processing, and safety reporting to ensure patient safety and regulatory compliance throughout oncology treatments.
• Project Management Proactive project management for oncology clinical trials including feasibility assessment, protocol development, study execution support, and milestone/budget alignment.
• Quality Assurance Services Risk-based Quality Assurance across oncology clinical trials using a Quality Management System meeting global regulatory requirements (FDA 21 CFR Parts 11, 50, 54, 56, 210, 211, 312, 314, 600, 820; ICH E6 GCP; EU GCP Directive).
• Regulatory Consulting and Support Expert regulatory strategy and support to navigate oncology trial approvals and compliance including IND applications, NDA submissions, and specialized therapy product development across US and EU jurisdictions.
• Biostatistical & Programming Services Advanced statistical design and programming for oncology trials including randomization plans, Statistical Analysis Plans (SAPs), CDISC-compliant submissions, and statistical representation at FDA meetings.
• Clinical Trial Management System (CTMS) Centralized, proprietary Clinical Trial Management System platform enabling planning, tracking, and oversight of oncology clinical trials with graphical/textual reports, customizable dashboards, enrollment tracking, adverse event monitoring, and safety review — used by Theradex for its CRO engagements and to deliver the NCI CTMS contract.
• Monitor Express Proprietary site-visit management system with seamless integration into clinical trial data, real-time visit tracking, automatic generation of trackable action items, and automated SIV and RMV Trip Reports for oncology site monitoring.
• Theradex IWRS - Patient Registration System Proprietary Interactive Web Response System enabling real-time patient registration, randomization, and drug assignment for oncology trials with highly configurable patient randomization, slot reservations, multi-step registrations, and enrollment reports — configurable without custom programming.
• Cohort Management Proprietary cohort management module enabling Lead Investigators to rapidly open/close cohorts and change accrual limits with automatic email notifications to study sites; fully integrated with the Theradex IWRS system.
• Drug Inventory Management Proprietary web-based drug inventory management system for ordering study drug and tracking shipments, replacements, and inventory at site and depot level, with automatic alerts when inventory drops below threshold.
• NCI Service Portal Proprietary resources portal for Theradex-managed NCI-CTMS trials providing access to NCI systems including OARS, Web Reporting, and instructional resources such as user guides and training materials.

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

Feature7 records

Partnerships

Two partnerships are on record, tiered core and flagship.

• Simsen DiagnosticscoreGTM or Marketing Partner · 18 November 2025Co-hosting Good Morning Meetings and UK Roadshow events on oncology clinical trials. Partnership includes exclusive morning meetings in Cambridge, London, and Oxford targeting pharma companies developing cancer therapies, focusing on ctDNA solutions and clinical trial strategies.
• National Cancer Institute (NCI)flagshipStrategic or Co-development Partner · 1 January 1982Since 1982, Theradex has held consecutive CTMS contracts with NCI for monitoring early phase clinical trials. Current agreement extends to May 2032. Partnership enables exposure to novel treatments and maintains institutional site and KOL relationships for 500+ studies over 10 years. All ETCTN protocols monitored through Theradex CTMS.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Medpace Holdings: Mid-size, therapeutically focused CRO with strong oncology and metabolic/endocrine franchises, operating a tech-enabled full-service model. Directly comparable in scale, therapeutic specialization strategy, and sponsor mix to Theradex.
• Novella Clinical (IQVIA): Was an oncology-focused mid-size CRO acquired by Quintiles/IQVIA in 2015 for its oncology trial operations. Provides a historical reference point for what a successful oncology specialist CRO looks like at scale and the likely acquisition trajectory for Theradex.
• Worldwide Clinical Trials: Mid-size full-service CRO with concentrated therapeutic focus in oncology, neuroscience, and rare disease. Mirrors Theradex's specialist-first positioning and mid-tier contract size capacity for global Phase I-III programs.
• Clinipace Worldwide: Mid-size full-service CRO with significant oncology and rare disease focus serving emerging biotech sponsors. Comparable therapeutic specialization and emerging-biotech customer profile to Theradex.

Broad incumbents

• Fortrea (formerly Labcorp Drug Development): Large full-service clinical development and commercialization services CRO with broad oncology offerings; overlaps with Theradex on Phase I-III oncology work but operates at meaningfully larger scale.
• ICON plc: One of the largest global full-service CROs (post-PRA Health Sciences merger) with broad therapeutic coverage including oncology. Competes with Theradex on larger global oncology programs but at significantly greater scale.
• Syneos Health: Large full-service biopharmaceutical solutions organization with clinical development and commercialization; competes for oncology sponsor work across multiple therapeutic areas at greater scale than Theradex.
• IQVIA: Largest global CRO with full-service oncology capabilities and broad therapeutic coverage; competes for enterprise pharma/biotech oncology trials but at vastly larger scale and with a full commercial/data services portfolio.
• Charles River Laboratories: Large CRO/CDMO offering discovery, preclinical, and clinical services including oncology trials; broader and larger than Theradex but relevant as an integrated-development competitor.

Others

• Calyx (formerly Bertelsmann): Specialized clinical technology provider for EDC and trial management. Comparable to Theradex as a peer technology ecosystem participant rather than a direct competitor; relevant given Theradex's own proprietary EDC/CTMS/IWRS stack.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/theradex

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Theradexå¨